MedTrace Logo

Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma

NCT00363831 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2010-07-28

No results posted yet for this study

Summary

Primary:

* To evaluate the efficacy of capecitabine in combination with oxaliplatin (XELOX) in terms of overall response rate (based on RECIST criteria) in patients with metastatic NPC without prior chemotherapy for relapse.

Secondary:

* To evaluate the efficacy profile of oxaliplatin (XELOX) in patients with metastatic NPC in terms of time to progression of disease, survival time, duration of response and complete response rate.
* To study the safety and tolerability of the regimen in patients with metastatic NPC.

Conditions

  • Nasopharyngeal Neoplasms

Interventions

DRUG

Oxaliplatin

130mg/m² infusion day 1, repeat every 21 days

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Iris Chan · Sanofi

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2009-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00363831 on ClinicalTrials.gov